Breaking News

Innoviva Completes Acquisition of La Jolla

Strengthens its footprint in the hospital and infectious disease spaces.

Author Image

By: Charlie Sternberg

Associate Editor

Innoviva Inc., a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, has successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.   La Jolla brings to Innoviva an established product portfolio, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or othe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters